Adding a Muscle Targeting Antibody to Semaglutide Cut Lean Mass Loss from 7.4% to 2.9% in a Phase 2 Trial

A 507-person trial found bimagrumab plus semaglutide protected lean mass while increasing fat loss. The drug remains investigational.

Have A Referral?